A-Alpha Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
A-Alpha Bio, Inc. - overview
Established
2017
Location
Seattle, WA, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in Washington, US, A-Alpha Bio, Inc. operates as a protein-protein interaction company. The company was founded by its CEO, David Younger, and CTO, Randolph Lopez. In June 2024, A-Alpha Bio, Inc.
raised USD 14. 5 million in venture funding from the Department of Defense. A-Alpha Bio offers a drug discovery platform focused on understanding and manipulating protein interactions. The firm employs synthetic biology and machine learning to measure and predict these interactions.
Their platform, AlphaSeq, generates extensive protein interaction data, while AlphaBind uses this data to create predictive models. The company plans to use the funds raised in June 2024 to carry out a project with the national lab for any future biological threats.
Current Investors
Madrona Venture Group, Washington Research Group, AME Cloud Ventures
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.aalphabio.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.